Unknown

Dataset Information

0

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.


ABSTRACT: Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been intensively studied, but we still have a limited appreciation of their neutralization breadth. Using a pseudovirus assay, we evaluated MAbs from clade B-infected donors and a clade B HIV(+) plasma against 93 viruses from diverse backgrounds. Anti-gp120 MAbs exhibited greater activity against clade B than non-B viruses, whereas anti-gp41 MAbs exhibited broad interclade activity. Unexpectedly, MAb 4E10 (directed against the C terminus of the gp41 ectodomain) neutralized all 90 viruses with moderate potency. MAb 2F5 (directed against an epitope adjacent to that of 4E10) neutralized 67% of isolates, but none from clade C. Anti-gp120 MAb b12 (directed against an epitope overlapping the CD4 binding site) neutralized 50% of viruses, including some from almost every clade. 2G12 (directed against a high-mannose epitope on gp120) neutralized 41% of the viruses, but none from clades C or E. MAbs to the gp120 V3 loop, including 447-52D, neutralized a subset of clade B viruses (up to 45%) but infrequently neutralized other clades (

SUBMITTER: Binley JM 

PROVIDER: S-EPMC524984 | biostudies-literature | 2004 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies.

Binley James M JM   Wrin Terri T   Korber Bette B   Zwick Michael B MB   Wang Meng M   Chappey Colombe C   Stiegler Gabriela G   Kunert Renate R   Zolla-Pazner Susan S   Katinger Hermann H   Petropoulos Christos J CJ   Burton Dennis R DR  

Journal of virology 20041201 23


Broadly neutralizing monoclonal antibodies (MAbs) are potentially important tools in human immunodeficiency virus type 1 (HIV-1) vaccine design. A few rare MAbs have been intensively studied, but we still have a limited appreciation of their neutralization breadth. Using a pseudovirus assay, we evaluated MAbs from clade B-infected donors and a clade B HIV(+) plasma against 93 viruses from diverse backgrounds. Anti-gp120 MAbs exhibited greater activity against clade B than non-B viruses, whereas  ...[more]

Similar Datasets

| S-EPMC109792 | biostudies-literature
| S-EPMC1489036 | biostudies-literature
| S-EPMC533925 | biostudies-literature
| S-EPMC10068833 | biostudies-literature
| S-EPMC3756680 | biostudies-literature
| S-EPMC3264345 | biostudies-literature
| S-EPMC1924550 | biostudies-literature
| S-EPMC189045 | biostudies-literature
| S-EPMC4285544 | biostudies-literature
| S-EPMC3934971 | biostudies-literature